Class information for:
Level 1: BENDAMUSTINE//TREANDA//BENDAMUSTIN

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
26196 215 30.1 73%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
1265 8379 CHRONIC LYMPHOCYTIC LEUKEMIA//HAIRY CELL LEUKEMIA//CLL

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 BENDAMUSTINE Author keyword 74 49% 51% 110
2 TREANDA Author keyword 4 75% 1% 3
3 BENDAMUSTIN Author keyword 3 100% 1% 3
4 GLOBAL NONCLIN DMPK Address 3 100% 1% 3
5 BENDAMUSTINE HYDROCHLORIDE Author keyword 1 50% 1% 2
6 R BAC Author keyword 1 100% 1% 2
7 RITUXIMAB REFRACTORY Author keyword 1 50% 1% 2
8 TREANDA R Author keyword 1 100% 1% 2
9 ABDOMINOPELVIC MASS Author keyword 1 50% 0% 1
10 AGGRESSIVE B CELL NON HODGKIN LYMPHOMA Author keyword 1 50% 0% 1

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 BENDAMUSTINE 74 49% 51% 110 Search BENDAMUSTINE Search BENDAMUSTINE
2 TREANDA 4 75% 1% 3 Search TREANDA Search TREANDA
3 BENDAMUSTIN 3 100% 1% 3 Search BENDAMUSTIN Search BENDAMUSTIN
4 BENDAMUSTINE HYDROCHLORIDE 1 50% 1% 2 Search BENDAMUSTINE+HYDROCHLORIDE Search BENDAMUSTINE+HYDROCHLORIDE
5 R BAC 1 100% 1% 2 Search R+BAC Search R+BAC
6 RITUXIMAB REFRACTORY 1 50% 1% 2 Search RITUXIMAB+REFRACTORY Search RITUXIMAB+REFRACTORY
7 TREANDA R 1 100% 1% 2 Search TREANDA+R Search TREANDA+R
8 ABDOMINOPELVIC MASS 1 50% 0% 1 Search ABDOMINOPELVIC+MASS Search ABDOMINOPELVIC+MASS
9 AGGRESSIVE B CELL NON HODGKIN LYMPHOMA 1 50% 0% 1 Search AGGRESSIVE+B+CELL+NON+HODGKIN+LYMPHOMA Search AGGRESSIVE+B+CELL+NON+HODGKIN+LYMPHOMA
10 FRAIL AND ELDERLY PATIENTS 1 50% 0% 1 Search FRAIL+AND+ELDERLY+PATIENTS Search FRAIL+AND+ELDERLY+PATIENTS

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 REFRACTORY INDOLENT 27 71% 10% 22
2 PROGRESSIVE SOLID TUMORS 17 75% 6% 12
3 MANTLE CELL 10 22% 19% 41
4 INDOLENT B CELL 10 40% 9% 19
5 RITUXIMAB REFRACTORY INDOLENT 9 83% 2% 5
6 PLUS RITUXIMAB 8 16% 20% 44
7 PHASE II MULTICENTER 4 13% 14% 30
8 BENDAMUSTINE MITOXANTRONE RITUXIMAB 3 100% 1% 3
9 CYTOSTASAN 3 100% 1% 3
10 INDOLENT 2 14% 7% 15

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Bendamustine: Rebirth of an Old Drug 2009 89 53 66%
Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel 2010 35 23 74%
Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma 2014 4 15 60%
Bendamustine A New Look at an Old Drug 2009 22 24 63%
A Canadian perspective on the safe administration of bendamustine and the prevention and management of adverse events 2014 3 11 64%
Bendamustine A Review of its Use in the Management of Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma 2010 13 33 85%
Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies 2012 3 62 81%
Bendamustine for the Treatment of Chronic Lymphocytic Leukemia and Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma 2009 13 56 70%
Bendamustine: something old, something new 2010 15 37 65%
Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma 2010 6 22 86%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 GLOBAL NONCLIN DMPK 3 100% 1.4% 3
2 CHRON LEUKEMIA MYELOMA PROGRAM 1 50% 0.5% 1
3 NONCLIN DMPK 1 50% 0.5% 1
4 ALTMARK KLINIKUM 0 33% 0.5% 1
5 DIPARTIMENTO ONCOL EMATOL PATOL PARATO P 0 33% 0.5% 1
6 HEMATOL ONCOLVANDERBILT INGRAM CANC 0 33% 0.5% 1
7 KLIN POLIKLIN INNERE MED ONKOL HAMATOL ENDOKRIN 0 33% 0.5% 1
8 SOD EMATOL 0 33% 0.5% 1
9 UO EMATOL TMO 0 33% 0.5% 1
10 UO ONCOEMATOL 0 33% 0.5% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000261644 FLUDARABINE//CHRONIC LYMPHOCYTIC LEUKEMIA//CLADRIBINE
2 0.0000202726 MANTLE CELL LYMPHOMA//T1114//BCL 1
3 0.0000121878 FOLLICULAR LYMPHOMA//NON HODGKINS LYMPHOMA//AGGRESSIVE NON HODGKINS LYMPHOMA
4 0.0000109945 PEPTICHEMIO//ALKYLATING PEPTIDES//HUMAN MYELOMA CELLS
5 0.0000094138 CD20//OFATUMUMAB//OBINUTUZUMAB
6 0.0000066726 MULTIPLE MYELOMA//LENALIDOMIDE//BORTEZOMIB
7 0.0000055912 BIOTECH DRUG DESIGN//HGEBIET ORGAN CHEM//CPR ANALYT
8 0.0000044604 1 3 DITHIOLIUM SALTS//DITHIOLIUM SALTS//ORTHO HYDROXYACETOPHENONES
9 0.0000040579 HODGKINS DISEASE//HODGKIN LYMPHOMA//HODGKINS LYMPHOMA
10 0.0000039857 POLYPHOSPHOESTERS//PHOSPHONATED METHACRYLATE//UNSATURATED POLYPHOSPHOESTER